Axsome Therapeutics, Inc. (AXSM)
|Net Income (ttm)||-113.63M|
|Day's Range||38.62 - 40.72|
|52-Week Range||19.38 - 87.24|
|Price Target||86.21 (+115.0%)|
|Est. Earnings Date||Nov 4, 2021|
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 ... [Read more...]
Financial PerformanceFinancial Statements
According to 14 analysts, the average rating for AXSM stock is "Strong Buy." The 12-month stock price forecast is 86.21, which is an increase of 114.99% from the latest price.
Axsome to host conference call and webcast on Monday, November 8, 2021 at 8:00 AM Eastern Time
Last month we discussed that Axsome Therapeutics stock is likely to continue to see higher levels after it rose 6% in a week following the U.S. FDA's acceptance of a new drug application for the company...
$100 million now available upon the potential FDA approval of AXS-05
These stocks are expected to put up big gains in a short amount of time.
Optimism among investors is growing for the possible approval of the biotech's MDD drug.
This biotech is down, but it isn't out just yet.
This beaten-down biotech regained some lost ground last month.
SHAREHOLDER ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses Over $...
NEW YORK, Sept. 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Axsome Therapeutics, In...
Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.
The risks are huge, but so are the potential returns.
A couple of months back we discussed that Axsome Therapeutics stock is likely to rebound after it fell nearly 20% in a month following the U.S. FDA's decision to pull the breakthrough therapy designatio...
Axsome (AXSM) is developing AXS-12 as a potential treatment for narcolepsy. The company initiates enrollment in a phase III study evaluating AXS-12.
NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders...
Axsome (AXSM) is seeking approval for its key pipeline candidate, AXS-07, as a potential acute treatment for migraine.
Axsome Therapeutics Inc Ranked Among Today's Top Shorts After The European Central Bank Says It May Slow Down Bond Pu...
The Dow Jones dipped about 40 points, the S&P 500 was flat, and the Nasdaq saw some mild gains, led by Big Tech stocks such as Apple, Facebook, and Amazon. Find opportunities in today's market with the ...
An unexpected regulatory setback weighed heavily on the biotech's shares last month.
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Stocks of biotech companies fighting COVID-19 have been great investments over the last two years. What stocks might zoom higher when the pandemic is over?
All three stocks on this list can more than double your money according to investment bank analysts who cover them.
There are still plenty of unknowns related to Axsome's FDA filing.
The company still doesn't have much to say about the FDA and its experimental new anti-depression drug.
FDA delays decision on Axsome Therapeutics' (AXSM) new drug application for AXS-05, a potential treatment for major depressive disorder.